Cheshire drug maker Alexion Pharmaceuticals Inc. has recruited to its board a veteran pharmaceutical executive whose deep knowledge of the Asian drug marketplace will enable the global launch of its blockbuster Soliris drug.
William R. Keller’s immediate appointment expands to eight the number of seats on Alexion’s board.
With more than 30 years of overseas sales and management experience, Keller is general manager of Keller Pharma Consultancy, which he founded in China.
He also is a senior consultant to the Shanghai Foreign Investment Development Board, and serves as the deputy general manager of Zhangjiang Biotech & Pharmaceutical Base Development Co. Ltd.
Keller spent several decades as an executive with Roche Group in Asia and South America.
Soliris treats a rare chronic disease called paroxysmal nocturnal hemoglobinuria (PNH), which causes a breakdown of red blood cells and leads to anemia.
